WO2021006615A1 - 화장품용 캡슐 - Google Patents
화장품용 캡슐 Download PDFInfo
- Publication number
- WO2021006615A1 WO2021006615A1 PCT/KR2020/008922 KR2020008922W WO2021006615A1 WO 2021006615 A1 WO2021006615 A1 WO 2021006615A1 KR 2020008922 W KR2020008922 W KR 2020008922W WO 2021006615 A1 WO2021006615 A1 WO 2021006615A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- capsule
- cosmetic
- group
- cosmetic capsule
- solvent
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/25—Silicon; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Definitions
- the present invention relates to a method of manufacturing a cosmetic capsule, and to a cosmetic capsule that can stably support an active ingredient, and has a large size, unlike the prior art, but has a less foreign body feeling when ruptured.
- Encapsulation is known as a method for solving the problem that the active ingredient loses its intrinsic properties due to factors such as light or heat during storage of cosmetics or the like, or its concentration is low due to a physical phenomenon such as evaporation. Such encapsulation not only increases the stability of the active ingredient, but also has the advantage of being able to activate the active ingredient at a time desired by the user, and for this reason, it is used in many industrial fields.
- a typical method of activating the encapsulated active ingredient is a method of gradually releasing or sustaining the active ingredient by inducing the destruction of the outer wall of the capsule due to factors such as pressure or the formation of a small hole in the outer wall of the capsule.
- Melamine-formaldehyde resin-based capsules are known as capsules that are widely used commercially, but there is a problem that formaldehyde, which is a toxic substance, must exist in the manufacturing process of microcapsules. For this reason, interest in new capsules without formaldehyde is increasing.
- liposome capsules As a solution to this, liposome capsules, coacervation, and microsponges have been proposed.
- these measures show limitations in that the stability of the capsule is reduced due to the surfactant and ionic components in the formulation, the carrying capacity of the active ingredient is lowered, or the release is not controlled. Therefore, it is insufficient to replace Melamine capsules.
- An inorganic material-based capsule such as silica has been proposed as a new alternative, but as the amphiphilicity of the core material increases, it is difficult to form the outer wall after the precursor organopolysiloxane moves to the interface, and thus, there is a problem in wide application. In addition, it has a disadvantage that it is difficult to control the degree of activation of the active ingredient due to its low elasticity and high hardness.
- the cosmetic industry is attempting to manufacture a capsule having a diameter of 100 ⁇ m or more in order to improve the aesthetic effect of the product and the visual satisfaction of the consumer.
- the use of outer wall materials increases during capsule manufacturing, which acts as a foreign body sensation when the capsule is ruptured, resulting in a problem of deterioration in customer satisfaction.
- the present invention comprises the steps of preparing an emulsion by mixing a continuous phase containing a polymer having two or more carboxyl groups and a dispersed phase containing a polyvalent cation transporter;
- an eco-friendly cosmetic capsule can be provided.
- FIG. 1 is a schematic diagram showing a manufacturing principle of a cosmetic capsule according to the present invention.
- the present invention relates to a method of manufacturing a cosmetic capsule.
- Such cosmetic capsules include preparing an emulsion by mixing a continuous phase containing a polymer having two or more carboxyl groups and a dispersed phase containing a polyvalent cation transporter;
- the emulsion After adjusting the pH of the emulsion to 10 or less, it can be prepared through a step of gelling.
- the cosmetic capsule according to the present invention comprises the steps of preparing a continuous phase containing a polymer having two or more carboxyl groups (hereinafter, step 1);
- step 2 Preparing a dispersed phase containing a polyvalent cation transporter (hereinafter, step 2);
- step 3 Mixing the continuous phase and the dispersed phase to prepare an emulsion (hereinafter, step 3); And
- step 4 After adjusting the pH of the emulsion to 10 or less, it can be prepared through a step of gelation (hereinafter, step 4).
- step 1 is a step of preparing a continuous phase.
- the continuous phase refers to a material maintained in a liquid state at room temperature, and generally refers to one or more of the solvents used in the process.
- the continuous phase includes a polymer having two or more carboxylic acid groups.
- the polymer having two or more carboxyl groups may serve as a material for forming the outer wall of the capsule produced during a gelling process to be described later.
- the polymer having two or more carboxyl groups can increase the dispersion stability of the emulsion at the interface of the emulsion formed by mixing with the dispersed phase, and meet the cation in the gelation process to form the outer wall through an ionic bond. Can be formed.
- the polymer having two or more carboxyl groups may include a compound represented by the following formula (1).
- R may include at least one selected from the group consisting of alkylene having 1 to 50 carbon atoms and cyclic hydrocarbon having 3 to 60 carbon atoms.
- alkylene refers to a straight or branched chain saturated or unsaturated hydrocarbon having the specified number of carbon atoms.
- cyclic hydrocarbon refers to a cyclic saturated or unsaturated hydrocarbon having the specified number of carbon atoms unless otherwise stated.
- the cyclic hydrocarbon may include an aromatic compound.
- an alkylene having 1 to 50 carbon atoms or a cyclic hydrocarbon having 3 to 60 carbon atoms may or may not contain one or more carboxyl groups and/or one or more hetero atoms.
- the alkylene having 1 to 50 carbon atoms may be specifically an alkylene having 1 to 30 carbon atoms
- the cyclic hydrocarbon having 3 to 60 carbon atoms is specifically a cyclic saturated hydrocarbon having 3 to 60 carbon atoms or an unsaturated hydrocarbon (aromatic Hydrocarbon).
- the polymer of Formula 1 is sodium alginate (Sodium Alginate), sodium acrylate (Sodium Acrylate), sodium carbomer (Sodium Carbomer), sodium acrylate / C10-30 alkyl acrylate crosspolymer (Sodium Acrylates/ C10-30 Alkyl Acrylate Crosspolymer) and sodium carboxymethyl cellulose (Sodium Carboxymethyl Cellulose).
- the polymer having two or more carboxyl groups may be included in an amount of 0.001 to 30 parts by weight, 0.01 to 10 parts by weight, 0.05 to 5 parts by weight, or 0.1 to 1 parts by weight based on the total weight (100 parts by weight) of the continuous phase. . If the content of the polymer having two or more carboxyl groups is less than 0.001 parts by weight, there is a concern that an emulsion is not formed, and if it exceeds 30 parts by weight, there is a concern that a problem of increasing the viscosity may occur.
- the polymer may be included in 0.001 to 100 parts by weight, 0.005 to 75 parts by weight, 0.01 to 50 parts by weight, or 1 to 10 parts by weight based on the total weight (100 parts by weight) of the dispersed phase.
- the solvent in the continuous phase is not particularly limited as long as it is possible to dissolve the polymer having two or more carboxyl groups, and water may be used in the present invention.
- step 2 is a step of preparing a dispersed phase.
- the dispersed phase refers to a material that is maintained in a liquid state at room temperature, and generally refers to one or more of the solvents used in the process.
- the dispersed phase includes a multivalent cation transporter.
- the multivalent cation transporter may release a multivalent cation at a pH of 10 or less during a gelling process to be described later.
- the polyvalent cation transporter can be dispersed in a dispersed phase, and when the pH is lowered in the future, it can react with a polymer having two or more carboxyl groups to release a polyvalent cation forming the outer wall of the capsule.
- the multivalent cation is a cation having a charge of 2 or more, and may connect between two or more carboxyl groups from which H + ions are dissociated.
- the polyvalent cation is an element having a charge of 2 or more upon ionization, and may be selected from alkaline-earth metal, semimetallics, transition metal, lanthanide, and actinide. , But is not limited thereto, but may be selected from Mg 2+ , Al 3+ , Ca 2+ , Zn 2+ , Ba 2+ and Sr 2+ .
- the polyvalent cation transporter is not limited thereto, but may be classified into a silicate compound, an oxide compound, and a salt compound including a polyvalent cation.
- the silicate compound includes a polyvalent cation in the chemical formula, and refers to a compound including a Si element and an O element.
- the silicate compounds may release polyvalent cations by acid-based reaction or redox reaction under conditions of pH 10 or less.
- Such silicate compounds include Aluminum Calcium Magnesium Potassium Sodium Zinc Silicate, Aluminum Calcium Sodium Silicate, Aluminum Iron Calcium Magnesium Germanium Silicate, Aluminum Iron Calcium Magnesium Germanium Silicate, Aluminum Iron Calcium Magnesium Zirconium Silicate, Aluminum Iron Silicate, Aluminum Silicate, Ammonium Fluorosilicate, Ammonium Silver Zinc Aluminum Silicate ), Calcium Aluminum Borosilicate, Calcium Magnesium Silicate, Calcium Silicate, Calcium Sodium Borosilicate, Calcium Sodium Phosphosilicate, Calcium Calcium Titanium Borosilicate, C24-28 Alkyldimethylsiloxy Trimethylsiloxysilicate, Lithium Magnesium Silicate, Lithium Magnesium Sodium Silicate, Magne
- the oxide compound includes a polyvalent cation in the chemical formula and refers to a compound containing an O element.
- the oxide compound may release a polyvalent cation by an acid-based reaction or redox reaction under conditions of pH 10 or less.
- These oxide compounds include aluminum/calcium/magnesium oxide (Aluminum/Calcium/Manganese Oxide), barium/calcium/silicon/titanium oxide (Barium/Calcium/Silicon/Titanium Oxide), Calcium Cerium Oxide, and calcium oxide ( Calcium Oxide), Calcium Peroxide, Aluminum Magnesium Oxide, Magnesium/Manganese/Titanium Oxide, Magnesium/Potassium/Silicone/Fluoride/Hydride/ Oxide (Magnesium/Potassium/Silicon/Fluoride/Hydroxide/Oxide), Magnesium/Potassium/Titanium Oxide,
- the salt compound refers to a material containing a polyvalent cation in the formula, and an anion that forms a complex with a polyvalent cation to make the total charge zero.
- the salt compound may release a polyvalent cation by acid group reaction or dissociation under conditions of pH 10 or less.
- anions that can be used as salt compounds include Fluoride, Chloride, Bromide, Iodide, Sulfide, Sulfate, Carbonate, and Phosphate.
- the diameter of the multivalent cation transporter may be 1 nm to 500 ⁇ m, 1.5 nm to 250 ⁇ m, or 2 nm to 100 ⁇ m.
- the multivalent cation transporter may be a multivalent cation transporter surface-treated with a compound for surface treatment.
- the polyvalent cation transporter may be surface-treated to achieve uniform dispersion in the dispersed phase.
- non-covalent surface treatment such as cetyltrimethylammonium bromide, cetyltrimethylammonium chloride, disteardimonium chloride and aluminum stearate as the surface treatment compound compound;
- a covalent surface treatment compound such as halosilane-based compound or alkoxysilane may be used.
- the content of the multivalent cation transporter may be 0.002 to 30 parts by weight, 0.006 to 25 parts by weight, or 0.011 to 20 parts by weight based on the total weight (100 parts by weight) of the dispersed phase. If the content of the polyvalent cation transporter is less than 0.002 parts by weight, there is a concern that a problem of not forming a capsule may occur, and if it exceeds 30 parts by weight, a problem of forming a capsule having a foreign body feeling due to a rapid reaction may occur.
- the solvent of the dispersed phase is not particularly limited as long as it is a solvent that is not mixed with the continuous phase.
- the dispersed solvent is a hydrocarbon (Hydrocarbon)-based solvent; A solvent containing an ether group; A solvent containing an ester group; A solvent containing a ketone group; Solvent containing benzene (Benzene); Haloalkane solvents; And it is possible to use at least one selected from the group consisting of a silicon (Silicone)-based solvent.
- Hydrocarbon-based solvents are linear or nonlinear such as pentane, hexane, cyclohexane, heptane, octane, isododecane, and dodecane. It can be selected from compounds of the structure, and the solvent containing an ether group is selected from ethyl ether, butyl ether, and methyl-t-butyl ether The solvent containing an ester group may be selected from ethyl acetate, butyl acetate, and ethyl butyrate.
- the solvent containing the ketone group may be methyl ethyl ketone (Methyl ethyl ketone), the solvent containing benzene (Benzene) is among benzene (Benzene), toluene (Toluene) and xylene (Xylene).
- the haloalkane-based solvent may be selected from dichloromethane, dichloroethane, chloroform, and carbon tetrachloride, and the silicon-based solvent is dime. It may be selected from Dimethicone and Cyclomethicone.
- the dispersed phase of the present invention may further include an active ingredient in addition to the above-described multivalent cation transporter.
- the active ingredient is a substance that is desired to maintain its activity by the resulting capsule, and the active ingredient may exhibit its activity after the outer wall of the capsule is destroyed. If the active ingredient is a liquid at room temperature, it can replace the dispersion phase, which is a solvent, otherwise it may vary depending on the solubility.
- a solvent one or more selected from the group consisting of fragrances, dyes, catalysts, antioxidants, and drugs may be used.
- step 3 is a step of forming an emulsion by mixing the above-described continuous phase and the dispersed phase.
- the content of the dispersed phase may be 1 to 90 parts by weight, 2 to 85 parts by weight, or 3 to 80 parts by weight based on the mixed weight (100 parts by weight) of the dispersed phase and the continuous phase.
- the step may be performed by adding a dispersed phase to the continuous phase, and may be performed under stirring.
- the stirring may be performed at 20 to 30° C., or at room temperature at 1 to 16000 RPM, 5 to 13000 RPM, or 10 to 10000 RPM.
- the step may be performed at a pH of 7 to 12.
- the size of the prepared emulsion may be 100 um or more.
- step 4 is a step of gelling after adjusting the pH of the emulsion to 10 or less.
- a cosmetic capsule may be manufactured through the above step. Specifically, as shown in Fig. 1, the capsule is formed at the interface formed after mixing the continuous phase and the dispersed phase. At the interface, a polymer having two or more carboxyl groups and a polyvalent cation released from a polyvalent cation transporter react (gelate) to form an outer wall of the capsule. In the present invention, it is possible to improve the foreign body feeling of the capsule by controlling the gelation rate.
- the polyvalent cation transporter releases a polyvalent cation, and the released polyvalent cation and a polymer having two or more carboxyl groups slowly gel at the interface, so that there are few toxic substances and high versatility and economy. It is possible to form a cosmetic capsule showing.
- polyvalent cations are released due to a drop in the pH of the continuous phase, and the gelation process is slow, so an outer wall capable of stabilizing the interface may be formed, although the strength is low, and thus a capsule having a less foreign body feeling can be manufactured. have.
- the step may be performed at pH 10 or less, pH 1 to 10, 2 to 9, or 3 to 8.
- the time interval between the step 3 of forming an emulsion and lowering the pH for forming the outer wall of the capsule may be 1 to 120 minutes, 2 to 90 minutes, or 3 to 60 minutes.
- gelation for capsule production may be performed at 0 to 100°C for 1 to 1440 minutes, 10 to 90°C for 2 to 720 minutes, and 20 to 80°C for 3 to 360 minutes.
- the gelation may be performed under stirring, and the stirring may be performed at 1 to 6000 RPM, 5 to 5000 RPM, or 10 to 4000 RPM.
- polyvalent cations are released as the pH decreases at the interface of the continuous phase and the dispersed phase, and the outer wall can be formed through gelation.
- the gelling may be performed in the presence of a dispersion stabilizer.
- the dispersion stabilizer may be used for the purpose of increasing the dispersibility of the capsule produced after the reaction.
- dispersion stabilizers gum arabic, polysaccharide, pectin, alginate, arabinogalactan, carrageenan, gellan gum, xanthan gum, guar gum, acrylate/acrylic polymer, starch, water-swellable clay, acrylate/aminoacrylate copolymer Coalescence, and mixtures thereof, maltodextrin; Natural gums such as alginate esters; Gelatin, protein hydrolysates and quaternized forms thereof; Synthetic polymers and copolymers such as poly(vinyl pyrrolidone-co-vinyl acetate), poly(vinyl alcohol-co-vinyl acetate), poly(maleic acid), poly(alkylene oxide), poly(vinylmethyl Ether), poly(vinylether-
- the time for curing may be 5 minutes to 48 hours, 7 minutes to 36 hours, or 10 minutes to 24 hours.
- the step of concentrating and/or drying the cosmetic capsule prepared as needed may be further performed.
- the pH can be adjusted by using an acid or a basic substance, and the conditions are not limited.
- a preservative, moisturizing agent, whitening effect component, wrinkle improvement component, etc., which are required for cosmetics, are dissolved in the external area, and the necessary components may be added, and the conditions are not limited.
- the present invention relates to a cosmetic capsule manufactured by the method for manufacturing the cosmetic capsule described above.
- the diameter of the cosmetic capsule according to the present invention may be 10 ⁇ m to 10,000 ⁇ m, 50 to 5,000 ⁇ m, or 100 to 1000 ⁇ m.
- the wall thickness of the capsule may be 0.05 to 100 ⁇ m.
- Step 1 A continuous phase was prepared by dispersing a polymer having two or more carboxyl groups in 89.8 g of distilled water.
- Step 2 A dispersion phase was prepared by adding 0.1 g of a polyvalent cation transporter to 9.9 g of Dodecane.
- Step 3 An emulsion was prepared by slowly putting the dispersed phase in the continuous phase under the condition of 50 RPM. Then, after lowering the pH to 10 or less, gelation was performed for 30 minutes to prepare a cosmetic capsule.
- Step 1 Sodium Alginate was added to 80 g of distilled water to prepare a continuous phase.
- Step 2 Prepare 9.9 g of Dodecane as a dispersed phase.
- Step 3 An emulsion was prepared by slowly putting the dispersed phase in the continuous phase under the condition of 50 RPM. Then, a solution in which calcium chloride (CaCl 2 ) was dissolved in 9 g of distilled water was added to the emulsion, followed by gelation for 30 minutes to prepare a cosmetic capsule.
- CaCl 2 calcium chloride
- Step 1 Sodium Alginate was added to 89.8 g of distilled water to prepare a continuous phase.
- Step 2 Prepare 9.9 g of Dodecane as a dispersed phase.
- Step 3 An emulsion was prepared by slowly putting the dispersed phase in the continuous phase under the condition of 50 RPM. Then, after adding magnesium aluminum silicate, the pH was lowered to 10 or less, and gelation was performed for 30 minutes to prepare a cosmetic capsule.
- Example 6 Example 7
- Example 8 Example 9
- Example 10 Example 11 Distilled Water 89.8 89.8 89.8 89.8 89.8 89.8 89.8 89.8 Polycation transporter
- the size of the capsule was measured using a Malvern Mastersizer 3000.
- 20 experienced panelists conducted sensory evaluation on a scale of'the lowest foreign body sensation' to 10 points of'the highest foreign body sensation', and then averaged the foreign body sensation by each manufacturing method.
- stability was compared by quantifying (using LC-MS) the size change of capsules stored at 40° C. for 1 month and oil in the capsule.
- Example 6 Example 7
- Example 8 Example 9
- Example 10 Example 11 Size ( ⁇ m) 145 156 138 149 150 141 Foreign body feeling (dots) 2.4 1.49 2.14 1.38 1.64 1.17 Size reduction after 1 month at 40 degrees (%) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 The amount of oil remaining after 1 month at 40 degrees (%) 99 99 99 99 99 99 99 99 99
- Comparative Example 1 As shown in Tables 3 and 4, the capsule of Comparative Example 1, which is a general capsule manufacturing method, exhibited a foreign body sensation, and a small sized capsule was prepared. In addition, in Comparative Example 2, no capsules were prepared.
- Example 1 to 11 capsules having a size of 100 ⁇ m or more were prepared.
- the capsule of the above example exhibited a lower foreign body feeling compared to Comparative Example 1, which is a general capsule manufacturing method.
- Comparative Example 1 is a general capsule manufacturing method.
- the amount of change in size is small and the change in oil content is small during long-term storage, indicating high stability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cosmetics (AREA)
Abstract
Description
비교예1 | 비교예2 | 실시예1 | 실시예2 | 실시예3 | 실시예4 | 실시예5 | ||
Distilled Water | 89 | 89.8 | 89.8 | 89.8 | 89.8 | 89.8 | 89.8 | |
다가양이온전달체 | Magnesium Aluminum Silicate | - | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Aluminum Calcium Sodium Silicate | - | - | - | - | - | - | - | |
Magnesium Potassium Fluorosilicate | - | - | - | - | - | - | - | |
Magnesium Sodium Fluorosilicate | - | - | - | - | - | - | - | |
Sodium Magnesium Aluminum Silicate | - | - | - | - | - | - | - | |
Lithium Magnesium Sodium Silicate | - | - | - | - | - | - | - | |
Calcium Oxide | - | - | - | - | - | - | - | |
CaCO 3 | - | - | - | - | - | - | - | |
CaCl 2 | 0.1 | - | - | - | - | - | - | |
Carboxylicgroup이2이상인고분자 | Sodium Alginate | 1 | 0.2 | 0.2 | - | - | - | - |
Sodium Acrylate | - | - | - | 0.2 | - | - | - | |
Sodium Carbomer | - | - | - | - | 0.2 | - | - | |
Sodium Acrylates/C10-30 Alkyl Acrylate Crosspolymer | - | - | - | - | - | 0.2 | - | |
Sodium Carboxymethyl Cellulose | - | - | - | - | - | - | 0.2 | |
Dodecane | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 |
실시예6 | 실시예7 | 실시예8 | 실시예9 | 실시예10 | 실시예11 | ||
Distilled Water | 89.8 | 89.8 | 89.8 | 89.8 | 89.8 | 89.8 | |
다가양이온전달체 | Aluminum Calcium Sodium Silicate | 0.1 | - | - | - | - | - |
Magnesium Potassium Fluorosilicate | - | 0.1 | - | - | - | - | |
Magnesium Sodium Fluorosilicate | - | - | 0.1 | - | - | - | |
Sodium Magnesium Aluminum Silicate | - | - | - | 0.1 | - | - | |
Lithium Magnesium Sodium Silicate | - | - | - | - | 0.1 | - | |
Calcium Oxide | - | - | - | - | - | 0.1 | |
CaCO 3 | - | - | - | - | - | - | |
Carboxylicgroup이2이상인고분자 | Sodium Alginate | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
Sodium Acrylate | - | - | - | - | - | - | |
Sodium Carbomer | - | - | - | - | - | - | |
Sodium Acrylates/C10-30 Alkyl Acrylate Crosspolymer | - | - | - | - | - | - | |
Sodium Carboxymethyl Cellulose | - | - | - | - | - | - | |
Dodecane | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 | 9.9 |
비교예1 | 비교예2 | 실시예1 | 실시예2 | 실시예3 | 실시예4 | 실시예5 | |
크기(μm) | 31 | - | 145 | 107 | 114 | 133 | 122 |
이물감(점) | 8.72 | - | 1.31 | 1.5 | 1.72 | 1.22 | 1.89 |
40도에서 1개월 후 크기 감소량(%) | - | - | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
40도에서 1개월 후 남아 있는 오일양(%) | - | - | 99 | 99 | 99 | 99 | 99 |
실시예6 | 실시예7 | 실시예8 | 실시예9 | 실시예10 | 실시예11 | |
크기(μm) | 145 | 156 | 138 | 149 | 150 | 141 |
이물감(점) | 2.4 | 1.49 | 2.14 | 1.38 | 1.64 | 1.17 |
40도에서 1개월 후 크기 감소량(%) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 |
40도에서 1개월 후 남아 있는 오일양(%) | 99 | 99 | 99 | 99 | 99 | 99 |
Claims (12)
- 카르복실기가 2개 이상인 고분자를 포함하는 연속상 및 다가 양이온 전달체를 포함하는 분산상을 혼합하여 에멀젼을 제조하는 단계; 및상기 에멀젼의 pH를 10 이하로 조절한 후, 겔화(gelation)하는 단계를 포함하는 화장품용 캡슐의 제조 방법.
- 제 1 항에 있어서,카르복실기가 2개 이상인 고분자의 함량은 연속상 전체 중량 대비 대비 0.001 내지 30 중량부인 것인 화장품용 캡슐의 제조 방법.
- 제 1 항에 있어서,연속상의 용매는 물인 것인 화장품용 캡슐의 제조 방법.
- 제 1 항에 있어서,다가 양이온 전달체는 pH 10 이하에서 다가 양이온을 방출하는 화합물인 것인 화장품용 캡슐의 제조 방법.
- 제 5 항에 있어서,다가 양이온 전달체는 다가 양이온을 포함하는 실리케이트(Silicate)류 화합물, 산화물 화합물 및 염 화합물로 이루어진 그룹으로부터 선택된 하나 이상을 포함하는 것인 화장품용 캡슐의 제조 방법.
- 제 1 항에 있어서,다가 양이온 전달체의 함량은 분산상 전체 중량 대비 0.002 내지 30 중량부인 것인 화장품용 캡슐의 제조 방법.
- 제 1 항에 있어서,분산상의 용매는 탄화수소(Hydrocarbon) 계열 용매; 에테르기(Ether group)를 포함하는 용매; 에스터기(Ester group)를 포함하는 용매; 케톤기(Ketone group)를 포함하는 용매; 벤젠(Benzene)을 포함하는 용매; 할로알칸(Haloalkane) 계열 용매; 및 실리콘(Silicone) 계열 용매로 이루어진 그룹으로부터 선택된 하나 이상을 포함하는 것인 화장품용 캡슐의 제조 방법.
- 제 1 항에 있어서,분산상은 유효성분을 추가로 포함하며,상기 유효성분은 향, 염료, 촉매, 항산화제 및 약물로 이루어진 그룹으로부터 선택된 하나 이상을 포함하는 것인 화장품용 캡슐의 제조 방법.
- 제 1 항에 있어서,에멀젼의 제조는 1 내지 16000 RPM의 조건에서 수행되는 것인 화장품용 캡슐의 제조 방법.
- 제 1 항에 있어서,겔화(gelation)는 0 내지 100℃, 1 내지 1440 분 및 1 내지 6000 RPM의 조건에서 수행되는 것인 화장품용 캡슐의 제조 방법.
- 제 1 항에 따른 제조 방법에 의해 제조되며,직경은 10 내지 10,000 ㎛이고, 벽 두께는 0.05 내지 100 ㎛인 화장품용 캡슐.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022500987A JP2022540598A (ja) | 2019-07-09 | 2020-07-08 | 化粧品用カプセル |
CN202080049926.3A CN114080212A (zh) | 2019-07-09 | 2020-07-08 | 化妆品用胶囊 |
US17/625,408 US20220273533A1 (en) | 2019-07-09 | 2020-07-08 | Capsule for cosmetics |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0082680 | 2019-07-09 | ||
KR20190082680 | 2019-07-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021006615A1 true WO2021006615A1 (ko) | 2021-01-14 |
Family
ID=74115060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/008922 WO2021006615A1 (ko) | 2019-07-09 | 2020-07-08 | 화장품용 캡슐 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220273533A1 (ko) |
JP (1) | JP2022540598A (ko) |
KR (1) | KR102444134B1 (ko) |
CN (1) | CN114080212A (ko) |
WO (1) | WO2021006615A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020064541A1 (en) * | 2000-04-21 | 2002-05-30 | Noa Lapidot | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
KR20110084151A (ko) * | 2008-07-31 | 2011-07-21 | 솔-겔 테크놀로지스 리미티드 | 활성성분을 포함하는 마이크로캡슐 및 금속 산화물 쉘, 그의 제조방법 및 그의 용도 |
KR20130008002A (ko) * | 2009-12-31 | 2013-01-21 | 솔-겔 테크놀로지스 리미티드 | 코어 안정화 마이크로캡슐, 이의 제조방법 및 이의 용도 |
KR20130031149A (ko) * | 2011-09-20 | 2013-03-28 | 주식회사 이레프 | 실리콘 겔 조성물 및 이로부터 구형 입자를 제조하는 방법 |
KR20160063661A (ko) * | 2014-11-27 | 2016-06-07 | 주식회사 엘지생활건강 | 킬레이팅 효과가 있는 폴리머를 이용한 알진 캡슐 붕해용 화장료 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149543A (en) * | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
CN101810595B (zh) * | 2009-02-25 | 2011-10-12 | 中国中化股份有限公司 | 一种海藻酸钙微胶囊制备方法 |
EP2305742B1 (en) * | 2009-10-01 | 2017-02-22 | Symrise AG | Spherical core-shell-particle |
EP2932956B1 (de) * | 2014-04-14 | 2017-12-27 | Symrise AG | Kapseln mit hoher Wirkstoffbeladung |
US20170216166A1 (en) * | 2014-10-01 | 2017-08-03 | International Flavors & Fragrances Inc. | Capsules containing polyvinyl alcohol |
US11655343B2 (en) * | 2016-03-24 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Alginate hydrogel compositions |
CN107970227A (zh) * | 2017-11-02 | 2018-05-01 | 天津大学 | 一种酪蛋白/海藻酸钠复合微囊的制备方法 |
-
2020
- 2020-07-08 WO PCT/KR2020/008922 patent/WO2021006615A1/ko active Application Filing
- 2020-07-08 US US17/625,408 patent/US20220273533A1/en active Pending
- 2020-07-08 KR KR1020200084072A patent/KR102444134B1/ko active IP Right Grant
- 2020-07-08 CN CN202080049926.3A patent/CN114080212A/zh active Pending
- 2020-07-08 JP JP2022500987A patent/JP2022540598A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020064541A1 (en) * | 2000-04-21 | 2002-05-30 | Noa Lapidot | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients |
KR20110084151A (ko) * | 2008-07-31 | 2011-07-21 | 솔-겔 테크놀로지스 리미티드 | 활성성분을 포함하는 마이크로캡슐 및 금속 산화물 쉘, 그의 제조방법 및 그의 용도 |
KR20130008002A (ko) * | 2009-12-31 | 2013-01-21 | 솔-겔 테크놀로지스 리미티드 | 코어 안정화 마이크로캡슐, 이의 제조방법 및 이의 용도 |
KR20130031149A (ko) * | 2011-09-20 | 2013-03-28 | 주식회사 이레프 | 실리콘 겔 조성물 및 이로부터 구형 입자를 제조하는 방법 |
KR20160063661A (ko) * | 2014-11-27 | 2016-06-07 | 주식회사 엘지생활건강 | 킬레이팅 효과가 있는 폴리머를 이용한 알진 캡슐 붕해용 화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR102444134B1 (ko) | 2022-09-16 |
KR20210006866A (ko) | 2021-01-19 |
US20220273533A1 (en) | 2022-09-01 |
CN114080212A (zh) | 2022-02-22 |
JP2022540598A (ja) | 2022-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2490663B1 (en) | Silicone compositions comprising a swollen silicone gel | |
EP2491065B1 (en) | Hydrophilically-modified silicone compositions | |
US7758888B2 (en) | Composition exhibiting enhanced formulation stability and delivery of topical active ingredients | |
US8017046B2 (en) | Skin cosmetic composition | |
US4940578A (en) | Hair preparation | |
EP1341524B1 (en) | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient | |
TWI444203B (zh) | 具有四級銨鹽之聚合性包覆物及用於製造其之方法 | |
EP0076515B1 (en) | Rapidly releasable microcapsules and method for the preparation thereof | |
HUT63325A (en) | Process for producing powdery pharmaceutical compositions with controlled release of active ingredient | |
KR860006266A (ko) | 지효성(持效性) 미크로 캡슐의 제조방법 | |
WO1996040073A3 (en) | Composition for sustained release of non-aggregated erythropoietin | |
KR20090125243A (ko) | 퍼옥사이드 및 레티노이드를 함유하는 국소 도포용 조성물 | |
BR0318049A (pt) | Processo para produção de uma forma farmacêutica oral com imediata desintegração e liberação de ingrediente ativo | |
HK1095526A1 (zh) | 乳酸聚合物及其製備方法 | |
WO2021006615A1 (ko) | 화장품용 캡슐 | |
CA2430824C (en) | Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient | |
JP3118192B2 (ja) | 油中水型乳化組成物及び皮膚化粧料 | |
WO2018044035A1 (ko) | 수중유형 화장료 조성물 | |
WO2010143802A1 (ko) | 안정한 역상 에멀젼 | |
WO2020054967A1 (ko) | 유용성 페이스트 또는 겔상의 오일을 포함하는 고형 비드의 제조방법 | |
WO2012115375A2 (ko) | 염모제 조성물 | |
WO2016098961A1 (ko) | 화장용 철분캡슐 및 이의 제조방법 | |
CA1315444C (en) | Fillers | |
WO2023038248A1 (ko) | 구형 메조 세공 실리카 및 이의 제조 방법 | |
JP2753642B2 (ja) | 二層型化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20836670 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022500987 Country of ref document: JP Kind code of ref document: A |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 25.04.2022) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20836670 Country of ref document: EP Kind code of ref document: A1 |